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Abstract
Understanding the molecular mechanisms underlying multi-drug resistance (MDR) is one of the major challenges in current
cancer research. A phenomenon which is common to both intrinsic and acquired resistance, is the aberrant alteration of
gene expression in drug-resistant cancers. Although such dysregulation depends on many possible causes, an epigenetic
characterization is considered a main driver. Recent studies have suggested a direct role for epigenetic inactivation of genes
in determining tumor chemo-sensitivity. We investigated the effects of the inhibition of DNA methyltransferase (DNMT) and
hystone deacethylase (HDAC), considered to reverse the epigenetic aberrations and lead to the re-expression of de novo
methylated genes in MDR osteosarcoma (OS) cells. Based on our analysis of the HosDXR150 cell line, we found that in order
to reduce cell proliferation, co-treatment of MDR OS cells with DNMT (5-Aza-dC, DAC) and HDAC (Trichostatin A, TSA)
inhibitors is more effective than relying on each treatment alone. In re-expressing epigenetically silenced genes induced by
treatments, a very specific regulation takes place which suggests that methylation and de-acetylation have occurred either
separately or simultaneously to determine MDR OS phenotype. In particular, functional relationships have been reported
after measuring differential gene expression, indicating that MDR OS cells acquired growth and survival advantage by
simultaneous epigenetic inactivation of both multiple p53-independent apoptotic signals and osteoblast differentiation
pathways. Furthermore, co-treatment results more efficient in inducing the re-expression of some main pathways according
to the computed enrichment, thus emphasizing its potential towards representing an effective therapeutic option for MDR
OS.
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Introduction
OS is one of the most prevalent primary malignant bone
tumors, showing high incidence in adolescence and above the age
of 50 years, and representing the second leading cause of cancer-
related death [1,2]. Approximately 20% of patients present with
metastasis at the time of initial diagnosis, and 50% of the rest of
patients are destined to develop metastatic disease during
treatment [3]. The unfavorable prognosis, and the low efficacy
of chemotherapy in patients with metastasis or relapsed disease
overall indicating a 5-year survival rate of ,20%, makes the
discovery of novel and improved therapeutic options particularly
urgent [4]. While OS pathogenesis is not yet clear, substantial
evidence suggests that OS should be considered a differentiation
disease [5]. The rationale behind this hypothesis is that the
terminal differentiation of osteoblasts derived from multipotent
mesenchymal stem cells, represents a highly structured process
whose control depends on a cascade of regulatory genes possibly
silenced during OS development. In particular, specific OS
molecular features suggest that both genetic and epigenetic
disruption of osteoblast differentiation pathways may occur during
tumor development [6–8].
Our driving hypothesis is that promoting differentiation and/or
circumventing differentiation defects should be considered before
undertaking effective OS adjuvant therapies. Based on the fact
that genetic and epigenetic processes are synergistic drivers of
malignancy, it is crucial to know the timing of such synergy.
Notably, the aberrant methylation can begin very early in cancer
progression, and mediate most of the important pathway
abnormalities, including loss of cell cycle control, alteration of
function of transcription factors and receptors, disruption of
normal cell-cell and cell-substratum interaction, inactivation of
signal transduction pathways, loss of apoptotic signals and genetic
instability, among other possible effects.
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Recently, cancer genome charts have addressed the prominent
role of epigenetic regulation. In particular, a central idea is that the
acquisition of additional epigenetic/genetic modifications may
lead to the development of drug resistance phenotypes [7,9,10].
Following this idea, a few specific aspects need to be highlighted.
First, epigenetic inactivation of genes can directly determine tumor
chemo-sensitivity, based on known studies [11–14] pointing out
the potential for influencing drug resistance and post-therapy
clinical outcomes [15,16]. Second, the so-called DNA methylation
and histone modifications paradox deserves special attention. Both
processes manifest through de-repression of oncogenes and
silencing of genes involved in key DNA damage responses
pathways and DNA repair during malignant transformation/
progression. However, at the gene expression scale such co-activity
of both DNA methylation and histone modifications can be either
independent or dependent [17], being centered on silencing gene
expression through modulation of transcription factors and
condensation of local chromatin structure [18]. Finally, epigenetic
modifications induce gene expression profiles, which vary widely
across cancers, reflecting a model in which methylation and/or
histone de-acetylation observed for certain genes would give a
growth or survival advantage to cancer cells. Consequently,
aberrant patterns of methylation would emerge depending on the
selective pressure for gene silencing in each specific cancer type
[19], and simultaneous inactivation of several pathways would
occur, compromising cell survival or cancer progression genes
[20].
The fact that epigenetic processes can be reverted, provides the
rationale for using chromatin re-modeling agents, DNMT
inhibitors and HDAC inhibitors, which induce the epigenetic re-
programming needed for the restoration of normal expression of
cancer-suppressor genes [21]. A substantial clinical impact is
expected from epigenetically-driven drugs designed to change
acquired drug resistance which is associated with epigenomic
features, and to prevent or reverse non-responsiveness to anti-
cancer drugs [16]. An important observation has been made about
the selection of MDR HosDXR150 cells by culturing sensitive Hos
cell lines in the presence of increasing doxorubicin doses: the
clones acquire cross-resistance to chemotherapeutic drugs by
overexpressing the P-glycoprotein, and by epigentically silencing
TP73, thus leading to knockout of apoptotic response [14]. This
observation has in turn represented the basis of a captivating
model for the identification of the molecular markers and
pathways contributing to OS progression and MDR phenotypic
selection. Such model is empowered to test potential ‘‘epigenetic
drugs’’ or treatment options for non-responsive OS patients. The
aim of the present work is to show the effectiveness of treatments
based on DNMT and HDAC inhibitors in inducing growth arrest,
apoptotic response and reprogramming of MDR OS phenotype
towards osteoblast differentiation. We demonstrated the influence
exerted over the expression of epigenetically modified genes, and
provided insights on the mechanisms by which epigenetic
therapeutic options can fight metastatic and non-responsive OS.
Materials and Methods
Ethics Statement
Doxorubicin-resistant osteosarcoma cells (HosDXR150) origin
from commercial Hos cell line (American type culture collection,
ATCC, Rockville, MD). HosDXR150 cells were previously
selected in our laboratory throughout a continuous exposure of
Hos cells to increasing doses of doxorubicin hydrochloride (DXR).
The characterization of this HosDXR150 osteosarcoma cells, has
been published by us in the paper: La Sala D et al. (2003)
Oncogene 22:3518–3529.
Cell Culture and Treatment
Doxorubicin-resistant osteosarcoma cells (HosDXR150) were
obtained by continuous exposure of parental OS sensitive Hos
cells (American type culture collection, ATCC, Rockville, MD) to
increasing doses of doxorubicin hydrochloride (DXR) 0.5–
150 ng/ml. This proprietary drug resistant HosDXR150 human
OS cell line was cultured in Dulbecco’s Modified Eagle Medium
(D-MEM) supplemented with 10% heat inactivated FCS at 37uC
in humidified, 5% CO2 atmosphere. 2,5 uM 5-Aza-29-deoxycy-
tidine (5-Aza-dC), 300 nM Trichostatin A (TSA) or both in
combination were added to cell culture. In the experiments where
both drugs were used, the TSA was added to medium culture 12h
after the 5-Aza-dC.
Cell Viability
Quantitative cell viability was measured by colorimetric assay
using cell proliferation (MTT kit) (Roche Molecular Biochemicals,
Germany). 56103 cells/well HosDXR150 cells were grown in
microtiter plates (96-well) in a final volume of 100 ul culture
medium. The incubation period of cells culture was 24, 36, 48, 72
and 96 hours in the absence (control) or presence of drugs. 10 ul of
MTT labeling reagent was added to each well at final
concentration 0.5 ug/ml. MTT was cleaved by growing cells to
form purple formazan crystals and allow quantification by
spectrophotometric analysis (ELISA). The optical density (OD)
values were measured at 550 nm on a multifunctional microplate
reader (Tecan, Durham, NC, USA). Cell viability was expressed as
the percentage of the ratio between the absorbance of drug-treated
cells relative to that of the control (untreated) cells according to the
formula: 1-experimental group OD/control group OD)6100%.
Results were plotted as the mean 6 SD (standard deviation) of 3
separate experiments from 6 determinations per experiment at
each experimental condition.
RNA Preparation
Total RNA samples were isolated from treated and untreated
HosDXR150 cells after 48h of cell cultures using TRIZOL
reagent (Invitrogen, CA, USA) according to the manufacturer’s
instructions. Concentration of purified RNA samples were
determined by A260 measurement and the quality was checked
by Lab-on-a-chip analysis (total RNA nanobiosizing assay, Agilent)
with the Agilent 2100 Bioanalyzer.
cDNA Microarray
RNAs isolated from treated and untreated HosDXR150, and
transcribed in cDNAs, were used to carry out the microarray
analysis. The cDNAs hybridization was done on a microarray chip
called MWG Human Cancer Array purchased from MWG Biotech
AG. This microarray contain 50-mer oligo-probes for 1920 genes
(1853 human genes associated with cancer, 27 control genes and
40 replicated genes). Microarray analysis was performed by MWG
Hybridization Service (MWG Biotech AG). For each experimental
point 10 ug of total RNA from a control (reference pool) and from
the sample (test pool) are labeled with Cy3 and Cy5 respectively,
utilizing a 2-step aminoallyl labeling. Co-hybridization with the
Cy3- and Cy5-probe is performed in an hybridization station on a
MWG Human Cancer Array (MWG Biotech AG). Every channel
(Cy3, Cy5) is scanned three times with increasing photomultiplier
gain settings using a Scanner 418/428 (Affimetrix) at 10 mm
resolution ensuring coverage of the full dynamic range. The
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produced 16-bit tiff images are used to perform the analysis. The
ImaGene pixel selection algorithms (BioDiscovery) determine
signal and background intensities for every individual spot. Spots
flagged as low quality were excluded from further analysis. Data is
freely available to researchers upon request. The requests can be
sent to Dr. Caterina Cinti, the corresponding author of this paper.
Data Analysis
The ImaGene intensity values are processed using MAVI
software (MWG Biotech AG), which solves saturation and
calculates the normalization parameters. GeneSight 4.0 (BioDis-
covery) is used to linearize the intensity values, calculate
differential expression and perform gene-clustering analysis. Genes
were selected as having at least 1.5-fold change in the log2 ratios of
expression level and statistically significant (Wilcoxon test) at the
0.01 cutoff P value; Benjamini and Hochberg correction for
multiple testing was applied. We used ‘‘R 3.0.1’’ for post-
processing of the micro-array results. The selected genes were
those whose log2 ratio was greater than or equal to 1.5 (up-
regulated) or less than or equal to 21.5 (down-regulated).
For GO term analysis, annotation was added using the packages
‘‘org. Hs.eg.db’’ v.2.9.0 and ‘‘GO.db’’ v.2.9.0. The frequency of a
GO term was defined as the number of times that the term
appears in a set of genes divided by the size of the set. The
difference between frequencies of two sets of genes (such as two
different treatments) was used as a first indicator of the differences
between those sets (a positive value points to terms enriched in the
first set and not in the second one, while a negative value suggests
the opposite). Venn diagrams were generated using ‘‘limma’’
v.3.17.23. For pathway enrichment analysis, we used the software
‘‘ClueGO 2.0.6’’ for ‘‘Cytoscape 3.0.1’’, applying the ‘‘Function’’
analysis mode and the ‘‘Compare’’ cluster analysis type (cluster
1 = up-regulated genes and cluster 2 = down-regulated genes) for
each of the treatments (DAC, TSA and combined DAC+TSA).
The statistical test used for enrichment in all cases was the right-
sided hypergeometric test. We selected only the terms with a p-
value smaller than 0.05 and at least three genes per term, with a
multiple testing correction using the Benjamini-Hochberg method.
The pathway databases included KEGG, REACTOME, Wiki-
Pathways and the Biological Process Gene Ontology, updated to
10.09.2013. The GO tree levels to use were set to a minimum of 5
and maximum 20. We fixed the value of the kappa estimator of
edge significance to 0.5. The other parameters of the software
were set to default values (for example, the ‘‘GO term fusion’’
option was not activated).
Quantitative Real Time- PCR (qRT-PCR)
Total RNA was extracted from treated and untreated
HosDXR150 cells using TRIZOL (Invitrogen, CA, USA)
according to the manufacturer’s instructions. For each sample,
2 mg of total RNA previously used for microarray analysis was
reversely transcribed using the QuantiTect Reverse Transcription
Kit (Qiagen Inc., Valencia, CA) according to the manufacturer’s
instructions. Gene expression was determined using the DyNAmo
Flash SYBR Green qPCR Kit (Thermo Scientific Inc., USA) on
the PikoReal Real-Time PCR System (Thermo Scientific Inc.,
USA). Primers were as follows:
N CASP10 sense 59-TCCCAAGCAAATGGGAGCTTCT-39,
reverse 59-TCATGGCCAGCCTTCAGATCAA-39;
N IL12A sense 59-ACCTCAGTTTGGCCAGAAACCT-39, re-
verse 59-AGAGTTTGTCTGGCCTTCTGGA-39;
N REL A sense 59-TTGAGGTGTATTTCACGGGACC-39,
reverse 59-ACTGCACCAGTGAGATCAGGA-39;
N TP73 sense 59-GACGAGGACACGTACTACCTT-39, re-
verse 59-CTGCCGATAGGAGTCCACCA-39;
N TP53 sense 59-ACGGAACAGCTTTGAGGTGCAT-39, re-
verse 59-TGTTGGACAGTGCTCGCTTAGT-39;
N TNFRSF6 sense 59-AAAGCTAGGGACTGCACAGTCA-39,
reverse 59-GTCCGGGTGCAGTTTATTTCCA-39;
N RBL2 sense 59-ATGCTGTCCCTGTGCAGAATGT-39, re-
verse 59-CTTGCACAGGAATGGTTACCGT-39;
N VEGFA sense 59-AGCTACTGCCATCCAATCGAGA-39,
reverse 59-TGCATGGTGATGTTGGACTCCT-39;
N ACTIN sense 59-TGCGTGACATTAAGGAGAAG-39, re-
verse 59-GCTCGTAGCTCTTCTCCA-39.
Amplification conditions were: 7 minutes at 95uC, followed by
40 cycles of 10 seconds at 95uC, 20 seconds at 60uC and 20
seconds at 72uC. All assays were carried out in triplicate. The
relative expression of target genes was evaluated using the
comparative cycle threshold method, with b-actin used for
normalization.
Western Blotting Analysis
Treated and untreated HosDXR150 cells were lysed in 50 mM
Tris/HCl, 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1%
Triton-X, 0.1 mM Na3VO4 plus protease inhibitors (Roche
Molecular Biochemicals, Germany). Equal amounts of proteins
were resolved on a 7% or 10% SDS-PAGE, transferred onto
nitrocellulose membranes, and then successively blocked with 5%
non-fat dry milk. Anti-RBL2 was from BD Transduction
Laboratories. Anti-FAS, anti-CASP10 and anti-IL12A were from
Sigma-Aldrich. Anti-TP73, anti-TP53, anti-actin and the horse-
radish peroxidase secondary antibodies were from Santa Cruz
Biotechnology. Primary antibodies were used at a dilution of
1:200. Secondary antibodies were used at a dilution of 1:5000.
Signals were acquired using the ImageQuant LAS 4000 (GE
Healthcare).
Results
We investigated the epigenetic mechanisms occurring in the
MDR OS phenotype by treating HosDXR150 cells with two
agents, first separately and then in combination:
i) A de-methylating agent alone, i.e. 5-Aza-dC (or DAC), an
inhibitor of DNMT;
ii) An inhibitor of histone de-acetylases (HDAC), i.e. the
Tricostatin A (TSA);
iii) A combination of i) and ii).
Figure 1 reports the anti-proliferative effects of the agents
described in i), ii) and iii). The cell viability during time exposure to
drug treatments was assessed by colorimetric assay using a cell
proliferation kit (MTT). While the single treatments (green line for
5-Aza-dC and blue line for TSA) have a limited effect in reducing
cell viability with time, up to 72 hours, the co-treatment induces
constant inhibition on cell proliferation at all times of treatment,
suggesting increased efficacy in reducing proliferation of MDR OS
cells compared to each of the individual treatments.
DNMT and HDAC inhibitors have a distinct mechanism of
action in determining the re-expression of epigenetically modified
genes. Therefore, the identification of genes with expression
modulated by the treatments is the first of our desired steps
designed to assess whether the agents may remove the transcrip-
tional repression of genes, and re-activate the apoptotic response
in MDR OS cells. In order to establish the effect of each
Epigenetic Treatments of MDR Osteosarcoma
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treatment, we performed cDNA microarray and functional
analyses targeting genes whose expression is drug-modulated
separately as well as jointly.
Table 1 summarizes the differentially expressed (DE) genes after
each treatment. The gene lists obtained from each condition were
divided into three groups by k-means clustering. The type of
regulation (up or down) for each of the resulting 9 clusters is
specified in the last column of Table 1. Venn diagrams indicating
the genes regulated after the three conditions are in Figure 2.
While up-regulated genes seem to be very specific to each
treatment, several down-regulated genes are present in both
separate and combined treatments. Both treatment-specific and
shared pathways linked to the genes listed in Figure 2 are provided
by functional enrichment. The specifications of the used software,
ClueGO [22], are described in Materials and Methods. Based on
the outcomes of such tool, Figures (Ss) S1, S2, and S3 show
functionally enriched clusters based on up- and down-regulated
genes. Tables (S1–8) report GO terms and corrected p-values for
all genes associated to each annotated functional cluster.
A summary is provided below to elucidate the main findings:
1. DCA treatment. 57 genes were found significantly up-
regulated, and 69 genes were found significantly down-
regulated. Up-regulated genes such as TP73, RBL2, CD47,
TNF-1B, SFN, MYC, CDK7, RAD50, WNT1 and IL-6-ST
identified GO terms listed as apoptosis, cytochrome C release,
adipogenesis and regulation of fat cell differentiation, cellular ion
homeostasis, regulation of embryonic and dorsal spin cord development
(Table S1 and Figure S1a). Down-regulated genes such as
MMP2, MAPK1, TBFRS7, REL A, SAFB, FES identified GO
terms listed as TGF-beta signaling, angiogenesis, IL-4 signaling,
cartilage development and cancer-related pathways. Furthermore,
clusters identified from other down-regulated genes include
negative regulation of cell migration, through ACVRL1, CXCL13
and MCC genes, and negative regulation of endothelial cell
proliferation, through ACVRL1, ENG and XDH genes (Table
S2 and Figure S1b). Table S3 and Figure S1c report
functionally enriched terms from both up-regulated genes
(IGF1, SFN and TP73) and down-regulated genes (BAI1 and
EI24), and refer to the p53 signaling pathway.
2. TSA treatment. 40 genes were found significantly up-
regulated, and for two of them, PDCD6 and TGFA, similar
up-regulation was observed after DAC. Then, 68 genes were
found significantly down-regulated. The up-regulated genes
identified GO terms listed as response to X-ray (BLM, ERCC6,
TP53), positive regulation of apoptosis signaling (AGFG1, LCK,
TP53) negative regulation of DNA replication and DNA metabolic
processes (BLM, RAD17, TP53), as well as regulation of reactive
oxygen species metabolic process involved in bone development (BMP7)
(Table S4 and Figure S2a). The down-regulated genes
identified GO terms as melanoma, ERK1 and ERK2 cascade,
myotube differentiation, enriched endochondrial ossification (BMP7,
CTSV, IGF1R and VEGFA), negative regulation of bone resorption
(calcium loss) (CD38 and VEGFA), negative regulation of FGFR
signaling (BRAF and FGF20), renal carcinoma and other (Table S5
and Figure S2b). Table S6 and Figure S2c report functionally
enriched terms including both up- and down-regulated genes,
identifying GO terms such as negative regulation of extrinsic apoptotic
signaling pathway (up-regulated: AGFG1, CFLAR and HTT;
down-regulated: IGFBP1, RELA), B cell differentiation (up-
regulated: ADAM17, MALT1, NCKAP1L, TP53; down-
regulated: GPR183, INHA, RAG1) and pancreatic cancer (up-
regulated: TGFA, TP53; down-regulated: BRAF, RELA,
VEGFA).
3. DAC-TSA treatment. 16 genes were found significantly
up-regulated, and 46 genes were found significantly down-
regulated. Some of the DE genes were previously found after
either DAC or TSA treatments. Regarding the 16 up-regulated
genes, S100A3, AXL, IL12A, XPC and FAS identified GO
terms such as positive regulation of natural killer cell activation, response
to UV-B, African trypanosomiasis, allograft rejection and Type I diabetes
mellitus (Table S7 and Figure S3a). The last three terms share
the FAS and IL12A genes, which have a role in extrinsic apoptotic
pathway. Among the down-regulated genes, 3 were also found in
relation to DAC treatment (CDH6, SMAD5, USP32), and 14
Figure 1. Anti-proliferative effects of 5-Aza-dC and/or TSA in
MDR osteosarcoma (Hos DXR150) cell line after 24, 36, 48, 72,
96 hours from treatment. The percentage of proliferation index +/2
the SD has been reported in the y axis. The mean 6 SD of 3 separate
experiments from 6 determinations per experiment at each experi-
mental condition. AZA (green line): cells treated with 5-Aza-29-
deoxcycitudine (DAC); TSA (bleu line): cells treated with Tricostatin A;
AZA+TSA (red line): cells treated with both drugs (DAC+TSA).
doi:10.1371/journal.pone.0095596.g001
Figure 2. Venn diagrams representing overlap between
differentially expressed genes after each treatment. (a) Overlap
between all DE genes after treatments with DAC, TSA and DAC+TSA in
MDR OS; (b) Overlap between up-regulated genes after treatments with
DAC, TSA and DAC+TSA; (c) Overlap between down-regulated genes
after treatment with DAC, TSA and DAC+TSA.
doi:10.1371/journal.pone.0095596.g002
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in relation to TSA treatment (CDKN2B, HHCM, SLC26A2,
FGF12, FOLR1, GML, PBOV1, SSTR2, ADAM17, ACTC1,
VEGFA, CBLB, CBFA2T2, CD38), while 8 genes were
common to all three treatments (STAG1, USP32P1,
SCGB2A1, PSG1, PSG3, BAI1, FKSG2, ST5). The down-
regulated genes after DAC-TSA treatment identified GO terms
such as extrinsic pathway for apoptosis and death receptor signaling
(ADAM17, CASP10 and FAS), T cell mediated immunity (HFE,
IL12A and TNFSF4), as well as T-helper 1 type immune response
(TNFSF4 and VEGFA), negative regulation of bone resorption, negative
regulation of bone and tissue remodeling (CD38 and VEGFA), positive
regulation of transforming growth factor (TGF) beta receptor signaling
(ADAM17 and CDKN2B), megakaryocyte differentiation
(CDKN2B and PSG1). These details are reported in Table
S8 and in Figure S3b.
Figure 3 and Figure 4 report, respectively, the main up- and
down-regulated pathway landscapes, together with the identified
gene lists which were significantly detected after the various
treatments.
Validation of 8 differentially expressed genes was performed by
qRT-PCR; in particular, TP73, RBL2, TP53, CASP10, IL12A and
FAS are selected among the up-regulated genes after specific
treatment, while REL A and VEGFA are down-regulated after
DAC and TSA, or TSA and DAC+TSA treatments. In Figure 5,
RBL2 and TP73 appear over-expressed after treatment with DAC
but not after treatment with TSA and DAC+TSA, while TP53 and
CASP10 are up-regulated by treatment with TSA, and IL12A and
FAS are up-regulated by treatment with DAC+TAS. REL A and
VEGFA are down-regulated: the former after treatment with DAC
or TSA, the latter after treatment with TSA or DAC+TSA, thus
confirming the cDNA microarray analysis. Up–regulated genes
were also validated by Western blotting (Figure 6), showing protein
expression time course increase, and following specific treatment.
Discussion
Despite extensive clinical trials and effective treatment regimens
or therapy plans based on surgery, radiation and systemic
chemotherapy, have determined improved clinical outcomes for
OS patients with either relapsed or developed metastasis the
therapeutic benefit of chemotherapy remains limited, suggesting
that new treatment options are needed. OS appears as a malignant
mesenchymal neoplasm characterized by defects in differentiation
of primitive osteoblastic cells, leading to high incidence of
metastasis and chemoresistance and poor prognosis [23]. In
particular, chemotherapy targets mainly proliferation cells, with-
out pinpointing potential differentiation defects of OS. Therefore,
a better understanding of the molecular pathogenesis of human
OS is required to be able to develop diagnostic and prognostic
markers, as well as targeted therapies for patients. Some of these
markers have been recently characterized in omics terms, i.e.
through multi-profile analyses, supporting in turn the identifica-
tion of new treatment options and the design of effective
personalized therapies, especially for those patients less responsive
to conventional chemotherapy [16].
Cancer stems from a cell clone with accumulated genetic and
epigenetic changes that influence its phenotype, and finally enable
Table 1. Up and down-regulated genes after each treatment (DAC, TSA, combination).
Cluster
N. of
Genes Genes Regulation
DAC –1 (69) CDH17, C14orf118, ST5, BRIT1, SEMA3B, SAFB, DAG1, RELA, SOTV, BRDT, GUK1, GSTA4, UBL3, TCF12, BCAN,
GTPBP1, USP32P1, MYBL1, TNFRSF18, VIPR1, TFPI2, T3G, OPRD1, DBCCR1, SCYA8, ISLR, PCTK1, MYCL2,
TSG101, PSG1, CDH6, FKSG2, VAULT1, RAB27B, ENG, HSD17B3, ACVRL1, CTSO, SLC1A5, CEACAM5, NY-REN-60,
MCC, CFTR, SIAT8B, FMR2P, BAI1, SLC29A2, MAPK1, MYC, MAGEA12, NPD002, MMP2, LY6E, FGF20, STAG1,
SSX3, FES, CD8B1, IFNB1, PGF, TFE3, PTGES, SCYB13, TNFRSF7, DAP5, MADH5, MGB2, EI24, PSG3
Down
DAC –2 (20) H4FM, BNIP3L, CD47, ALDH9, CEP110, LYZ, TGFA, ITGA3, ABCC4, MFI2, CP, INS, MLLT3, MLLT4,
SH2B2, ZNF670, PARM1, FOXO1A, FASN, XDH
Up
DAC –3 (38) IL6ST, TP73, NR2C2, TIMP4, CDK7, PSG, TNFRSF1B, PDCD6, IL6, ANXA7, MFGE8, LHX1, HOXC6, NEF3,
TOP3B, IGF1, GGH, PBX3, WNT1, CTNND1, SLC19A1, TNFSF18, RBL2, TP53BPL, CPN2, RAD50, ELL2,
HTATIP2, ATP6B1, LMOD1, ASNA1, HRMT1L2, SFN, MYB, NCOA6, RAB6, TNFSF7, KLK10
Up
TSA –1 (9) RELA, CD38, VEGF, CDKN2B, FKSG2, ROS1, GML, STAG1, MGB2 Down
TSA –2 (40) LCK, XYLB, BLM, MSH4, RAB13, XPA, RAD17, PDCD6, SPINK1, TGFA, FAT1, ERCC6, LCN2, HD, EVI2B,
PLCB3, MALT1, S100A2, ADAMTS6, RIPK3, CASP10, HEM1, CTAG1, TAX1BP1, USP4, TP53, YF13H12,
CXCR4, SDCCAG43, CYP1B1, HRB, CFLAR, CRABP1, MCC, RAB1, BMP7, FAPA, MARK3, UBE1L, TRPM1
Up
TSA –3 (59) ACTC, ALK, ST5, CTSL2, RAG1, MAGEB3, F9, CALCR, LCP1, EBI2, MARS, BCL9, TIE, ABCC4, RFXAP, FOLR1,
CDH11, HHCM, USP32P1, PDGFRL, SSX1, IGFBP1, BECN1, SSTR2, INHA, MLLT3, IGF1R, GNA13, DYRK1,
ARCN1, PSG1, WWOX, BRAF, LIFR, MUC13, MGAT5, ADRB2, MAGEB1, NAPSA, CRYBA1, MGB1, CBFA2T2,
TNFSF15, BAI1, HGF, UC28, IMPG1, CBLB, SLC26A2, RAB23, LECT2, LHCGR, ADAM17, MTAP, FGF20,
NEO1, TRB, FGF12, PSG3
Down
DAC+TSA –1 (16) TNFRSF6, COL1A2, S100A4, XPC, FOXM1, FHL2, GTPBP1, GAGE7, LENG4, MS4A12,
NDN, SLC22A1L, DPAGT1, S100A3, AXL, IL12A
Up
DAC+TSA –2 (4) FKSG2, CBFA2T2, GML, STAG1 Down
DAC+TSA –3 (42) ACTC, ST5, FCGR1A, CBLC, POU2AF1, TNFSF4, CD38, VEGF, FOLR1, FOLH1, CDKN2B,
HHCM, USP32P1, CASP10, BIN2, SSTR2, LIG3, PSG1, STX6, CDH6, HFE, PLOD2, ZNF45,
SERPINA2, STEAP, CHP2, IFNA1, ETV1, NY-REN-60, SH3BP2, BAI1, UC28, STMN2, P2RX1,
CBLB, SLC26A2, ADAM17, REG3A, FGF12, MADH5, MGB2, PSG3
Down
Treatment groups indicated by ‘Cluster’ obtained by k-means clustering.
Associated gene number and list in second and third columns, respectively.
The type of regulation is specified in the last column.
doi:10.1371/journal.pone.0095596.t001
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its escape from the normal controls of proliferation [24]. Recently,
cancer genomes charts have increasingly addressed the central role
of epigenetic regulators in cancer, which may result in the
acquisition of additional epigenetic modifications leading to drug
resistance. Epigenomes may lead to differences in intrinsic
sensitivity of cancer to chemotherapy, depending on the specific
function of the inactivated genes, and may promote survival in the
presence of drugs by allowing the selection of drug-resistant tumor
cells [10,15].
The synergy between DNA methylation and histone post-
translational modifications can begin very early in cancer
progression, and the profiles of gene promoter hypermethylation
differ in each cancer type [19]. Several DNMT and HDAC
inhibitors have been proposed to reverse the epigenetic aberra-
tions, and induce the re-expression of all de novo methylated genes.
In turn, this action could induce the reprogramming of cancer cells
toward differentiated cells or chemo-sensitivity of MDR cancer
cells [16,21]. OS may be caused by genetic and epigenetic
alterations representing a cross-sectional endpoint leading to the
disruption of osteoclast differentiation pathways from mesenchy-
mal stem cells [6,25]. Therefore, the identification of critical
epigenetic defects, which allow the OS tumors to escape from the
osteoblast differentiation and apoptotic response, may lead to the
design of effective epigenetic therapeutic strategies.
The applications in literature of hierarchical clustering to DNA
copy number profiles of several OS cell lines and clinical samples
have revealed that the difference in quality of results between cell
lines and patient samples is not systematic [8]. Thus, OS cell lines
can be valuable tools to study the molecular mechanisms at the
basis of OS development and progression. In this work, we used
the MDR OS cells, HosDXR150, obtained by continuous
exposure of the parental OS sensitive cell line to increasing doses
of doxorubicin, as a model to evaluate the effect of epigenetic
drugs in inducing reprogramming and reverting of chemo-
resistance phenotype. Previously, La Sala et al. [14] showed that
an OS cell line (Hos), even with a functionally inactivated TP53
and RB1/TP105 homozygous deletion, undergoes apoptosis upon
doxorubicin treatment through E2F1/TP73-dependent pathway.
The p73-dependent apoptotic response is no longer functional in
the MDR and metastatic variant HosDXR150 cells due to the
presence of DNMT and the replacement of histone acetyl-
transferase enzyme (HAT/p300) with HDAC1 on the TP73
promoter. This mechanism, in turn, triggers the DNA methylation
and de-acetylation of histone tails, and consequently the epigenetic
silencing of TP73 in MDR HosDXR150 cells, suggesting that
further epigenetic alterations occur to clonally select the MDR OS
phenotype. These observations have important clinical conse-
quences as epigenetic modifications provide the rationale for
epigenetic drugs to change reversible drug resistance-associated
epigenomes, and prevent or reverse non-responsiveness OS to
chemotherapeutic drugs.
Figure 3. Pathways landscape. Summary of functional enrichment results showing the main pathways separated by treatment, and shared across
treatments, with corresponding lists of up-regulated genes.
doi:10.1371/journal.pone.0095596.g003
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Figure 4. Pathway landscape. Summary of functional enrichment results showing the main pathways separated by treatment, and shared across
treatments, with corresponding lists of down-regulated genes.
doi:10.1371/journal.pone.0095596.g004
Figure 5. Quantitative RT-PCR analysis. The mRNA levels of selected genes were evaluated in all treated cells and compared to control. Data are
normalized to b-actin. The relative expression is given as the ratio between treated and untreated cells and reported as mean 6 SD. The black line
represents normalized control values (*P,0.05 by Student’s t test).
doi:10.1371/journal.pone.0095596.g005
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We showed that DAC and TSA treatments and co-treatment
induce the up-regulation of many genes, and that the co-treatment
of MDR OS cells with both agents result more effective in
reducing cell proliferation than any of the two component
treatments, even if positive regulation of both intrinsic and
extrinsic apoptotic signals seem to be the most important effect
after all such treatments. However, the nature of this regulation
appears highly complex, with a number of pathways being
enriched in up- or down-regulated genes for all treatments, and
some for each specific treatment. As a result of our multiple
analyses, lesser genes appear up- and down- regulated in the
combined treatment, suggesting that the effects are not simply
additive but interactive, and in a quite complex way, as confirmed
by functional enrichment analysis. GO and functional enrichment
analyses of the microarray data, which were performed to identify
groups of differentially expressed genes after all treatments,
allowed us to identify several pathways and regulatory processes
that might explain the experimentally observed effects.
The evidence from treatment-dependent complex regulatory
processes suggests a few remarks. First of all, our data show that in
the re-expression of epigenetic silenced genes (up-regulated genes),
a very specific regulation takes place involving either methylation
or de-acetylation, or even the two combined mechanisms.
Considering the up-regulated genes reported in Venn analysis,
58 genes are exclusively re-expressed after DAC treatment, 40
genes after TSA and only 16 genes after both treatments. The
differential expression profile of up-regulated genes described in
this protocol seems to be mutually exclusive, and suggests that
epigenetic modifications such as methylation and de-acetylation
have occurred either independently or simultaneously to deter-
mine gene silencing in MDR OS. In particular, we observed that
the re-activation of apoptotic response in MDR OS cells can be
driven by TP73-dependent apoptotic signal in cells treated with
DAC, previously described as silenced [14], and by over-
expression of other pro-apoptotic genes such as AGFG1, LCK,
BLM, ERCC6, AXL, XCP, FAS, CASP10 and IL12A, mainly
involved in extrinsic apoptotic signaling in cells treated with TSA
or DAC plus TSA. Interestingly, only the combined treatment is
able to induce re-expression of IL12A, which has a role in the
activation of extrinsic apoptotic pathway together with FAS and
CASP10. However, it has also shown to have a prominent role in
inflammatory responses, as well as remarkable antitumor proper-
ties by inducing immune response and inhibiting metastatic
potential of OS cells via a mechanism involving the FAS/FAS
ligand pathway [26,27].
Other genes such as IL6, IL6ST, BMP7, ATP6B1, IGF1,
WNT1, TNFs and ALPL, previously described as down-regulated
in OS and indicated as driver genes in regulating osteoblast
differentiation, adipogenesis, skeletal and bone development
[6,25,28], result epigenetically modified in our experimental
setting and are mainly up-regulated following the DAC treatment.
Instead, TSA and co-treatment seem to be more effective in
inhibiting negative regulators of endochondral ossification, and
bone resorption and remodelling pathways via ACVR1, FGFRs,
CDH11, ADRB2, CD38 and VEGFA. Interestingly, the treat-
ments also induce the down-regulation of MMP2 and HGF genes,
which have been shown over-expressed in OS patients with poor
clinical outcome, and manly contribute to aggressive OS behavior,
and the up-regulation of S100A6 and CXCR4, two genes
described as inhibitors of metastasis.
Especially with regard to the down-regulated genes, MMP2’s
expression is correlated with poor prognosis and with the ability of
Figure 6. Western Blotting analysis. The expression of some proteins measured at different treatment times, and involved in apoptotic signaling
and/or cell cycle control, regulated by specific treatments. A total of 40 mg of whole cell lysate from HosDXR150 treated with 5-Aza-2-deoxicytidine
(DAC) or Trychostatin A (TSA) or combined treatment (DAC+TSA) at different times (24, 36, 48, 72 and 96 hours) was electrophoretically fractioned in
SDS-PAGE. The levels of protein expression increased beginning at 36 hours for RBL2, CASP10 and FAS, or at 48 hours for TP73, TP53 and IL12A, and
reached a maximum at 96 hours. Beta-actin was used to normalize.
doi:10.1371/journal.pone.0095596.g006
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cell to metastatize [29]; this gene is down-regulated following the
DAC treatment. Instead, for HGF, a cytokine that stimulates cell
proliferation and mobility [30], a down-regulation is observed
after the TSA treatment. On the contrary, S100A6, which is
described to play a role in inhibition of cell mobility and
anchorage-independent growth [31], is up-regulated following
co-treatment, and CXCR4, which plays a role in cytoskeleton
rearrangement, adhesion to endothelial cells, and directional
migration [32], is up-regulated after the TSA treatment.
Other important pathways manly related to angiogenesis,
oxidative stress like IL4 and ERK1/2 signaling, cell migration
and proliferation like TGF-beta and cancer immunosurveillance
signaling were down-regulated after the treatments. In particular,
the DAC treatment seems to be more effective in inhibiting
angiogenesis, cell migration/proliferation and oxidative stress
through TGF-beta and IL-4 signaling respectively, while TSA
seems more efficient in inducing the repression of cancer
immunosurveillance beyond bone resorption and remodeling
signaling. Finally, all the mentioned pathways that are down-
regulated by the co-treatment suggest that the effects of each drug
are additive, even if cancer immune-surveillance is silenced in
addition to the above mentioned signals. The suppression of
immune-surveillance may be a mechanism by which tumors resist
to immune detection and elimination, and natural killer T cells
play an immunoregulatory role in the biology of the OS immune-
surveillance [33].
The overall of these results strongly indicates that MDR OS
cells acquired growth and survival advantage by epigenetic
inactivation of both multiple apoptotic signals and osteoblast
differentiation pathways and by overexpression of genes involved
in angiogenesis and cancer immunosurveillance signaling path-
ways, major related to cancer progression and MDR phenotype.
Particular gene-specific epigenetic profile acted to silence the
tumor-suppressor genes and, among the three protocols of
treatment, the co-treatment seems to be a more efficient
therapeutic strategy in inducing tumor cell growth arrest and the
reprogramming of MDR OS phenotype toward osteoblast
differentiation.
Kresse et al. [8] analysed genes differentially expressed on OS
cell lines and primary tumors, compared to normal bone cells, and
generated a dataset of genes including those significantly
methylated in their chemo-sensitive OS samples. Just 13 genes
(3.3%) of the total genes described in literature as methylated
genes are found differentially expressed in their study. A
comparison between this set of methylated genes with the genes
which we found up-regulated in the MDR OS cells after the
treatments (DAC or TAS, or combined), revealed that 6 of 13
genes described in Kresse’s dataset as methylated in OS
(CRABP1, RIPK3, SLC22A18, TNFRSF1B, TP73 and WNK2)
were up-regulated in the MDR OS cells after one of the
treatments. In contrast to their description of no effects of DAC
treatment in reactivating the expression of these epigenetic
silenced genes in OS cells, we found that TNFRSF1B and TP73
genes can be up-regulated by DAC treatment, that CRABP1,
RIPK3 and WNK2 are up-regulated by TSA treatment, and
SLC22A18 by the co-treatment.
In summary, our results indicate the following as the main
findings:
1) The mechanisms by which the listed genes are silenced can
refer to different epigenetic modifications. Consequently,
different epigenetic treatments are needed to induce cancer
cell re-programming in MDR OS;
2) The 6 genes described by Kresse et al. [8] could be considered
the first events in tumor development, while the other genes
that were found differentially expressed only in our dataset,
can be silenced during cancer progression and MDR
transformation;
3) The suggested epigenetic therapy could represent an effective
adjuvant therapy for MDR OS, allowing to promote and
circumvent differentiation defects of primitive osteoblast cells,
and to sensitize them for a subsequent chemotherapy
approach.
As a final remark, the follow-up of this study will involve a
deeper investigation of regulatory mechanisms, utilization of other
OS cell lines, and extension of the analysis to clinical samples.
Conclusions
OS is the most frequent malignant primary bone tumor and
represents a main cause of cancer-related death in children and
adolescents. The currently available conventional therapy, which
consists of multi-agent surgery, chemotherapy, and radiation, is
unfortunately not totally adequate for OS treatment. Innovative
drugs and treatment approaches are needed to aim at further
improvements of the outcomes observed in patients. This study
shows that the epigenetic silencing of most cancer suppressor and
osteoblast differentiation genes, yields clonal selection of the MDR
phenotype. Treatments involving both DNMT and HDAC
inhibitors can induce cell growth arrest and the reprogramming
of MDR-OS cells towards osteoblast differentiation. We believe
that this study offers through expression experiments, analysis and
annotations an understanding of mechanisms by which epigenetic
therapeutic options may be useful to fight metastatic and non-
responsive OS. As a final remark, we foresee in the follow-up a few
novel directions of research to be pursued, for example a deeper
investigation of regulatory mechanisms, the utilization of other OS
cell lines, and the extension of the analysis to clinical samples.
Supporting Information
Figure S1 Functionally enriched terms for the up- and down-
regulated genes after DAC treatment. (a) Pathways and GO terms
enriched in up-regulated genes after DAC treatment; (b) Pathways
and GO terms enriched in down-regulated genes after DAC
treatment; (c) Pathways and GO terms enriched in both up- and
down-regulated genes. ClueGO has provided the functional clusters;
the number of associated genes for each cluster are reported within
the bars.
(TIF)
Figure S2 Functionally enriched terms after TSA treatment. (a)
Pathways and GO terms enriched in up-regulated genes after
TSA; (b) Pathways and GO terms enriched in down-regulated
genes after TSA; (c) Pathways and GO terms enriched in both up-
and down-regulated genes. ClueGO has provided the functional
clusters. The number of associated genes for each cluster are
reported within the bars.
(TIF)
Figure S3 Functionally enriched terms after combined DAC+
TSA treatment. (a) Pathways and GO terms enriched in up-
regulated genes after DAC+TSA; (b) Pathways and GO terms
enriched in down-regulated genes after DAC+TSA. ClueGO has
provided the functional clusters. The number of associated genes
for each cluster are reported within the bars.
(TIF)
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Table S1 Functionally enriched terms for the up-regulated genes
after DAC treatment. TermIDs as from GO (Gene Ontology); WP
corresponds to WikiPathways, used with KEGG and REAC-
TOME as database sources.
(DOCX)
Table S2 Functionally enriched terms for the down-regulated
genes after DAC treatment. TermIDs as from GO (Gene
Ontology); WP corresponds to WikiPathways, used with KEGG
and REACTOME as database sources.
(DOCX)
Table S3 Functionally enriched terms including both up- and
down-regulated genes after DAC treatment. TermIDs as from GO
(Gene Ontology); WP corresponds to WikiPathways, used with
KEGG and REACTOME as database sources.
(DOCX)
Table S4 Functionally enriched terms for the up-regulated genes
after TSA treatment. TermIDs as from GO (Gene Ontology); WP
corresponds to WikiPathways, used with KEGG and REAC-
TOME as database sources.
(DOCX)
Table S5 Functionally enriched terms for the down-regulated
genes after TSA treatment. TermIDs as from GO (Gene
Ontology); WP corresponds to WikiPathways, used with KEGG
and REACTOME as database sources.
(DOCX)
Table S6 Functionally enriched terms including both up- and
down-regulated genes after TSA treatment. TermIDs as from GO
(Gene Ontology); WP corresponds to WikiPathways, used with
KEGG and REACTOME as database sources.
(DOCX)
Table S7 Functionally enriched terms for the up-regulated genes
after combined DAC+TSA treatment. TermIDs as from GO
(Gene Ontology); WP corresponds to WikiPathways, used with
KEGG and REACTOME as database sources.
(DOCX)
Table S8 Functionally enriched terms for the down-regulated
genes after combined DAC+TSA treatment. TermIDs as from
GO (Gene Ontology); WP corresponds to WikiPathways, used
with KEGG and REACTOME as database sources.
(DOCX)
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